甲氧苄啶/磺胺甲恶唑在治疗耐碳青霉烯类药物引起的感染中的作用
The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant .
作者信息
Luterbach Courtney L, Boshe Ashley, Henderson Heather I, Cober Eric, Richter Sandra S, Salata Robert A, Kalayjian Robert C, Watkins Richard R, Hujer Andrea M, Hujer Kristine M, Rudin Susan D, Domitrovic T Nicholas, Doi Yohei, Kaye Keith S, Evans Scott, Fowler Vance G, Bonomo Robert A, van Duin David
机构信息
Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina.
Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio.
出版信息
Open Forum Infect Dis. 2018 Dec 14;6(1):ofy351. doi: 10.1093/ofid/ofy351. eCollection 2019 Jan.
Abstract
In the Consortium on Resistance Against Carbapenems in and other (CRACKLE), trimethoprim-sulfamethoxazole (TMP-SMX) had a limited role in the treatment of less severe carbapenem-resistant (CRE) infections, especially urinary tract infections. Of tested CRE, only 29% were susceptible to TMP-SMX. Development of resistance further limits the use of TMP-SMX in CRE infections.
摘要
在碳青霉烯类耐药肠杆菌科细菌及其他细菌耐药性研究联盟（CRACKLE）中，复方新诺明（TMP-SMX）在治疗不太严重的耐碳青霉烯类肠杆菌科细菌（CRE）感染，尤其是尿路感染方面作用有限。在检测的CRE中，只有29%对复方新诺明敏感。耐药性的产生进一步限制了复方新诺明在CRE感染中的使用。
相似文献
1
The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant .
Open Forum Infect Dis. 2018 Dec 14;6(1):ofy351. doi: 10.1093/ofid/ofy351. eCollection 2019 Jan.
2
Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study.
J Glob Antimicrob Resist. 2019 Jun;17:168-172. doi: 10.1016/j.jgar.2018.12.001. Epub 2018 Dec 14.
3
Trimethoprim-resistant Enterobacteriaceae in urinary tract infection.
Can Med Assoc J. 1975 Jun 14;112(13 Spec No):54-8.
4
Dissemination of Trimethoprim-Sulfamethoxazole Drug Resistance Genes Associated with Class 1 and Class 2 Integrons Among Gram-Negative Bacteria from HIV Patients in South India.
Microb Drug Resist. 2017 Jul;23(5):602-608. doi: 10.1089/mdr.2016.0034. Epub 2016 Nov 17.
5
Epidemiologic features of urinary infections due to enterobacteriaceae resistant to nalidixic acid and trimethoprim.
Scand J Infect Dis. 1981;13(3):195-202. doi: 10.3109/inf.1981.13.issue-3.07.
6
Characterization of trimethoprim-sulfamethoxazole resistance genes and their relatedness to class 1 integron and insertion sequence common region in gram-negative bacilli.
J Microbiol Biotechnol. 2015 Jan;25(1):137-42. doi: 10.4014/jmb.1409.09041.
7
Antimicrobial Resistance and Urinary Tract Infection Recurrence.
Pediatrics. 2016 Apr;137(4). doi: 10.1542/peds.2015-2490. Epub 2016 Mar 11.
8
A comparison of trimethorprim-sulfamethoxazole with sulfamethoxazole alone in infections localized to the kidneys.
Can Med Assoc J. 1975 Jun 14;112(13 Spec No):9-12.
9
Prophylaxis of urinary tract infection in persons with recent spinal cord injury: a prospective, randomized, double-blind, placebo-controlled study of trimethoprim-sulfamethoxazole.
Am J Med. 1993 Aug;95(2):141-52. doi: 10.1016/0002-9343(93)90254-m.
10
Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999.
Int J Antimicrob Agents. 2001 Aug;18(2):121-7. doi: 10.1016/s0924-8579(01)00369-7.
引用本文的文献
1
Urinary Tract Infections Caused by and Prolonged Treatment with Trimethoprim/Sulfamethoxazole.
Microorganisms. 2025 Feb 14;13(2):422. doi: 10.3390/microorganisms13020422.
2
Ciprofloxacin for the Treatment of Infections Caused by Carbapenemase-Producing Gram-Negative Bacteria.
Antibiotics (Basel). 2024 Nov 26;13(12):1138. doi: 10.3390/antibiotics13121138.
3
Treating infections caused by carbapenemase-producing Enterobacterales (CPE): a pragmatic approach to antimicrobial stewardship on behalf of the UKCPA Pharmacy Infection Network (PIN).
JAC Antimicrob Resist. 2020 Oct 5;2(3):dlaa075. doi: 10.1093/jacamr/dlaa075. eCollection 2020 Sep.
4
Trimethoprim-sulfamethoxazole as de-escalation in ventilator-associated pneumonia: a cohort study subanalysis.
Eur J Clin Microbiol Infect Dis. 2021 Jul;40(7):1511-1516. doi: 10.1007/s10096-021-04184-8. Epub 2021 Feb 24.
5
How to manage KPC infections.
Ther Adv Infect Dis. 2020 May 14;7:2049936120912049. doi: 10.1177/2049936120912049. eCollection 2020 Jan-Dec.
6
Whole genome sequencing snapshot of multi-drug resistant Klebsiella pneumoniae strains from hospitals and receiving wastewater treatment plants in Southern Romania.
PLoS One. 2020 Jan 30;15(1):e0228079. doi: 10.1371/journal.pone.0228079. eCollection 2020.
本文引用的文献
1
Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant .
Infect Drug Resist. 2018 Sep 12;11:1461-1472. doi: 10.2147/IDR.S150447. eCollection 2018.
2
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
3
Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series.
Infection. 2017 Apr;45(2):209-213. doi: 10.1007/s15010-016-0968-x. Epub 2017 Feb 9.
4
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
5
Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients.
Transpl Infect Dis. 2015 Dec;17(6):800-9. doi: 10.1111/tid.12450. Epub 2015 Nov 5.
6
Emergence of Carbapenem-Resistant Klebsiella pneumoniae: Progressive Spread and Four-Year Period of Observation in a Cardiac Surgery Division.
Biomed Res Int. 2015;2015:871947. doi: 10.1155/2015/871947. Epub 2015 May 4.
7
Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance.
Clin Microbiol Infect. 2014 Dec;20(12):O1117-20. doi: 10.1111/1469-0691.12714. Epub 2014 Dec 12.
8
Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network.
Antimicrob Agents Chemother. 2014 Jul;58(7):4035-41. doi: 10.1128/AAC.02636-14. Epub 2014 May 5.
9
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.
Lancet Infect Dis. 2009 Apr;9(4):228-36. doi: 10.1016/S1473-3099(09)70054-4.
Zotero 插件